Cardiovascular Outcomes in COVID-19 Patients Treated with Paxlovid: A Multicenter Retrospective Study

Area of Science:

• Cardiology
• Infectious Diseases
• Pharmacology

Background:

• The COVID-19 pandemic spurred rapid development of treatments like Paxlovid, an oral antiviral.
• While effective for high-risk individuals, Paxlovid's cardiovascular impact requires further investigation.
• COVID-19 itself poses significant cardiovascular risks, complicating treatment assessments.

Purpose of the Study:

• To evaluate the cardiovascular outcomes and mortality associated with Paxlovid treatment in COVID-19 patients.
• To assess the short-term and long-term effects of Paxlovid on cardiovascular events and survival.

Main Methods:

• Retrospective cohort study utilizing data from Taiwan's Chang Gung Memorial Hospital System (January-December 2022).
• Propensity score matching created comparable groups: 606 patients treated with Paxlovid and 1,809 untreated patients.
• Primary outcomes included cardiovascular events and all-cause mortality over a 12-month follow-up.

Main Results:

• Paxlovid significantly reduced all-cause mortality at 3 and 6 months post-COVID-19 infection.
• This survival benefit was not sustained at the 12-month follow-up.
• Venous thromboembolism rates were significantly higher in the Paxlovid group at 6 and 12 months.

Conclusions:

• Paxlovid offers short-term survival advantages for COVID-19 patients.
• Treatment with Paxlovid is linked to an increased risk of venous thromboembolic complications.
• Careful patient selection and monitoring are essential, particularly for individuals with pre-existing cardiovascular conditions.